KLK3 and cancer: As expected, the probability of PCa death within 10 years was considerably lower in the PSA era than in the pre-PSA era, reflecting both lead time (the period from screen identification to the anticipated time of clinical diagnosis in the natural disease course) and overdiagnosis (when patients with screen-detected cancers may die from other causes before the time of clinical diagnosis) among detected cases, as well as screening benefit.